Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization


Related Publications

Suter E, Misfeldt R, Mallinson S, Wilhelm A, Boakye O, Marchildon G, et al. Comparative Review of the Policy Landscape of Team-based Primary Health Care Service Delivery in Western Canada. Alberta Health Services; 2014.
Laberge M, Pang J, Walker K, Wong ST, Hogg W, Wodchis WP. QUALICOPC (Quality and Costs of Primary Care) Canada: A focus on the aspects of primary care most highly rated by current patients of primary care practices. Ottawa, ON: Canadian Foundation for Healthcare Improvement; 2014.
McGregor MJ, Abu-Laban RB, Ronald L, McGrail KM, Andrusiek D, Baumbusch J, et al. Nursing Home Characteristics Associated with Resident Transfers to Emergency Department. Canadian Journal on Aging. 2012;33(1):38-48.
Koehoorn M, McLeod CB, Fan JK, McGrail KM, Barer ML, Cote P, et al. Do private clinics or expedited fees improve wait- or return-to-work times for injured workers following knee surgery? Healthcare Policy. 2011;5(3):17-26.
Sutherland JM, Barer ML, Evans RG, Crump RT. Will paying the piper change the tune? Healthcare Policy. 2011;6(4):16-24.

Publication Topics

Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization

Publication TypeJournal Article
Year of Publication2006
AuthorsCaetano PA, Lam JM, Morgan SG
JournalClinical therapeuticsClin.Ther.
Pages1411 - 24; discussion 1410
Date Published2006
KeywordsAntihypertensive Agents/therapeutic use, Drug Prescriptions, Drug Utilization/standards, Guideline Adherence, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hypercholesterolemia/drug therapy, Hypertension/drug therapy, Patient Compliance
AbstractBACKGROUND: Long-term utilization of prescription drugs for chronic conditions such as hypertension and/or hypercholesterolemia is a reality for millions of individuals, yet therapies may be discontinued before they can exert their beneficial effect. Several studies have measured the mean duration of therapy (ie, persistence) using administrative health databases. However, the terminology and methodology used for measuring persistence varied across studies, making it difficult to compare persistence rates. OBJECTIVES: The objectives of this study were to identify currently used measures of persistence and to propose a standard operational definition for use in administrative database analyses of drug utilization. METHODS: MEDLINE was searched for English-language articles published between January 1997 and June 2005 that quantified the concepts of persistence, adherence, compliance, or continuity with statin or antihypertensive therapy using administrative prescription claims databases. The conceptual and operational definitions of persistence used in the identified studies were categorized and applied to prescription-refill data for a hypothetical patient to compare the durations of persistence resulting from each method. RESULTS: Thirty-one articles were identified and reviewed. Few of the studies explicitly stated the conceptual definition of persistence used. Five methods of measuring persistence were identified: anniversary models, minimum-refills models, refill-sequence models, proportion-of-days-covered models, and hybrid models. When these models were applied to data for the hypothetical patient, total persistence with drug therapy ranged from 7 days to >1 year. CONCLUSIONS: There continue to be inconsistencies in the definition of persistence and the methods by which it is measured. A standard operational definition of persistence should be 2-dimensional, quantifying not only the total duration of therapy, but also the intensity of medication-taking within this interval.
Citation Key293